ClinicalTrials.gg
CompletedNCT02036645Updated Jun 3, 2019Results posted

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

A Phase 1 interventional study of MEDI1814 for IV injection and MEDI1814 for Subcutaneous Injection in Mild-Moderate Alzheimer's Disease and Healthy Elderly, sponsored by AstraZeneca. Completed at 10 sites in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Alzheimer Disease by AstraZeneca — none open to participants now, none under way, none of them phase 3. Alzheimer Disease · AstraZeneca.

Enrollment
9th of 23
77 · median 52
Started
2014
with 4 others
Phase 1
15 of 24
none open now
Registered
18th of 24
by date

Among the 24 studies in Alzheimer Disease by AstraZeneca, this one is the 9th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2014, is one of 15 in phase 1, and was the 18th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

None of the 24 studies in Alzheimer Disease by AstraZeneca is open now. The open studies under Alzheimer Disease, anywhere →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Alzheimer Disease by AstraZeneca as a file.
02

Study summary

The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.

03

Conditions studied

  • Mild-Moderate Alzheimer's Disease
  • Healthy Elderly

Browse trials for

04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Male and female (non child bearing potential) subjects Mild-moderate Alzheimer's Disease

Exclusion Criteria History or evidence of significant disease Presence of psychiatric disorder which would affect completion of the study Current serious or unstable illness

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    MEDI1814 IV

    Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.

    Biological: MEDI1814 for IV injection

  • Placebo comparator
    IV Placebo

    Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.

    Biological: MEDI1814 for IV injection · Biological: IV Placebo

  • Experimental
    MEDI1814 Sub Cutaneous Injection

    2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort

    Biological: MEDI1814 for Subcutaneous Injection

  • Placebo comparator
    Subcutaneous Placebo

    2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort

    Biological: Placebo for Subcutaneous Injection

Interventions

  • BiologicalMEDI1814 for IV injection

    Monoclonal antibody for IV Injection

  • BiologicalMEDI1814 for Subcutaneous Injection

    Monoclonal antibody for subcutaneous injection

  • BiologicalIV Placebo

    Placebo for IV injection

  • BiologicalPlacebo for Subcutaneous Injection

    Subcutaneous Placebo Injection

06

What researchers measure

Primary outcomes

  1. Tolerability as Measured by Participant Withdrawal for an Adverse Event

    Tolerability measured by participant withdrawal for an adverse event from randomization through end of study

    Time frame: 4 months SAD; 7 months MAD

Secondary outcomes

  1. Area Under the Concentration Time Curve (AUC) Time 0 to t (28 Days After 1st Dose SAD and MAD and After 3rd Dose in MAD, Day 57)

    Area Under the Concentration time curve (AUC) time 0 to t; calculated from Just prior to dose administration start to 28th day after dose (pre infusion, during infusion, 1,2,4,8,24,48 hr 7, 14, 21, and 28 day)

    Time frame: 1 month

  2. Maximum Plasma Concentration (Cmax) of Medi1814

    Maximum plasma concentration (Cmax) of Medi1814 during 28 day period after dose administration start (prior to dosing, during infusion, 1, 2, 4, 8, 24, 48 hr, 7, 14,21, and 28 days)

    Time frame: 1 month

  3. Mean Termination Half Life (t 1/2) of Medi1814

    Mean termination half life (t 1/2) of Medi1814 during 28 day period after dose administration start (SAD Day 1 dose, MAD 3rd dose)

    Time frame: 1 month

  4. Biomarkers: Amyloid-beta in Cerebral Spinal Fluid (Two Amyloid Bets Peptides of 40 and 42 Amino Acids Were Assessed)

    Biomarkers: Amyloid-beta in cerebral spinal fluid, mean percent change from baseline

    Time frame: Day 29 in SAD; Day 85 in MAD

  5. Biomarker: Total Amyloid-beta 1-42 in Plasma

    Biomarker: Total Amyloid-beta 1-42 in plasma, mean percent change from baseline

    Time frame: Day 29 in SAD; Day 85 in MAD

  6. Medi1814 Concentration in CSF Samples

    Medi1814 concentration in CSF Samples; number of sampled subjects with a value above the lower limit of quantification

    Time frame: SAD Day 29; MAD Day 85

  7. Immunogenicity: Anti-drug Antibody Titer

    Immunogenicity: Anti-drug antibody titer, subject counted if titer 50 or greater on any test, else 0 if all \<50

    Time frame: 4 months SAD (6 tests over 4 months; week 1, 2, 4, 8, 12, 16); 7 months MAD (7 monthly tests)

07

Results

Posted Jun 3, 2019
Limitations and caveats
Although 11 subjects were in both a SAD and a MAD cohort, summaries were for those assigned to the cohort regardless of participation in any other cohort

Participant flow

261 screening visits in 193 individuals were required to randomize 45 subjects into 6 Single Ascending Dose (SAD) cohorts and 32 subjects into 4 Multiple Ascending Dose (MAD) cohorts.

SAD Cohorts : Study Part 1
Participant flow — SAD Cohorts : Study Part 1
MilestonePlacebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADPlacebo: MADMedi1814 300 mg IV: MADMedi1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
Started1236666600000
Completed1236566500000
Not completed000100100000
Withdrew: Lost to follow-up000000100000
Withdrew: Withdrawal by subject000100000000
MAD Cohorts: Study Part 2
Participant flow — MAD Cohorts: Study Part 2
MilestonePlacebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADPlacebo: MADMedi1814 300 mg IV: MADMedi1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
Started000000086666
Completed000000086666
Not completed000000000000

Outcome measures

PrimaryTolerability as Measured by Participant Withdrawal for an Adverse Event

Tolerability measured by participant withdrawal for an adverse event from randomization through end of study

Time frame:
4 months SAD; 7 months MAD
Reported as:
Number · Participants
Tolerability as Measured by Participant Withdrawal for an Adverse Event
ParticipantsPlacebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC : SADPlacebo: MADMedi1814 300 mg IV: MADMedi1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
Tolerability as Measured by Participant Withdrawal for an Adverse Event000000000000
SecondaryArea Under the Concentration Time Curve (AUC) Time 0 to t (28 Days After 1st Dose SAD and MAD and After 3rd Dose in MAD, Day 57)

Area Under the Concentration time curve (AUC) time 0 to t; calculated from Just prior to dose administration start to 28th day after dose (pre infusion, during infusion, 1,2,4,8,24,48 hr 7, 14, 21, and 28 day)

Time frame:
1 month
Reported as:
Geometric mean · ng x day/mL
Area Under the Concentration Time Curve (AUC) Time 0 to t (28 Days After 1st Dose SAD and MAD and After 3rd Dose in MAD, Day 57)
ng x day/mLMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADMedi1814 300 mg IV: MADMedi1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
First Dose (day 1-29)80.5 ± 61.1455 ± 19.71550 ± 26.34040 ± 28.04420 ± 30.7120 ± 51.9710 ± 24.21690 ± 75.34490 ± 24.2162 ± 69.2
Third dose (day 57-85)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA1150 ± 37.92680 ± 747150 ± 27.3134 ± 57.0
Statistical analysis
  • Medi1814 25 mg IV: SAD vs Medi1814 100 mg IV: SAD vs Medi1814 300 mg IV: SAD vs Medi1814 900 mg IV: SAD vs Medi1814 1800 mg IV: SAD · Regression, Linear · Slope: 0.93 · 95% CI 0.82 to 1.04Since an Estimation approach was taken for the statistical analysis, no p-values were calculated
  • Medi1814 300 mg IV: MAD vs Medi1814 900 mg IV: MAD vs Medi1814 1800 mg IV: MAD · Regression, Linear · Slope: 1.01 · 95% CI 0.71 to 1.30Since an Estimation approach was taken for the statistical analysis, no p-values were calculated
SecondaryMaximum Plasma Concentration (Cmax) of Medi1814

Maximum plasma concentration (Cmax) of Medi1814 during 28 day period after dose administration start (prior to dosing, during infusion, 1, 2, 4, 8, 24, 48 hr, 7, 14,21, and 28 days)

Time frame:
1 month
Reported as:
Geometric mean · ng/ml
Maximum Plasma Concentration (Cmax) of Medi1814
ng/mlMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADMedi1814 300 mg IV: MADMedi1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
First dose (day 1-29)10.2 ± 42.738.7 ± 30.9102 ± 14.7341 ± 19.3424 ± 36.13.59 ± 51.483.9 ± 22.3172 ± 77.2496 ± 24.410.1 ± 81.4
Third dose (day 57-85)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA96.7 ± 38.3185 ± 110536 ± 32.37.56 ± 38.5
Statistical analysis
  • Medi1814 25 mg IV: SAD vs Medi1814 100 mg IV: SAD vs Medi1814 300 mg IV: SAD vs Medi1814 900 mg IV: SAD vs Medi1814 1800 mg IV: SAD · Regression, Linear · Slope: 0.90 · 95% CI 0.81 to 0.98Since an Estimation approach was taken for the statistical analysis, no p-values were calculated
  • Medi1814 300 mg IV: MAD vs Medi1814 900 mg IV: MAD vs Medi1814 1800 mg IV: MAD · Regression, Linear · Slope: 0.96 · 95% CI 0.65 to 1.27Since an Estimation approach was taken for the statistical analysis, no p-values were calculated
SecondaryMean Termination Half Life (t 1/2) of Medi1814

Mean termination half life (t 1/2) of Medi1814 during 28 day period after dose administration start (SAD Day 1 dose, MAD 3rd dose)

Time frame:
1 month
Reported as:
Mean · days
Mean Termination Half Life (t 1/2) of Medi1814
daysMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADMedi1814 300 mg IV: MADMedi1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
First dose (day 1-29)17.2 ± 0.9417.0 ± 2.1617.1 ± 2.7819.0 ± 2.2318.3 ± 7.6919.8 ± 3.56NA ± NANA ± NANA ± NANA ± NA
Third dose (day 57-85)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA14.2 ± 1.8616.2 ± 1.6120.4 ± 5.3816.4 ± 3.29
SecondaryBiomarkers: Amyloid-beta in Cerebral Spinal Fluid (Two Amyloid Bets Peptides of 40 and 42 Amino Acids Were Assessed)

Biomarkers: Amyloid-beta in cerebral spinal fluid, mean percent change from baseline

Time frame:
Day 29 in SAD; Day 85 in MAD
Reported as:
Mean · % change
Biomarkers: Amyloid-beta in Cerebral Spinal Fluid (Two Amyloid Bets Peptides of 40 and 42 Amino Acids Were Assessed)
% changePlacebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADPlacebo: MADMedi1814 300 mg IV: MADMedi1814 900 mg: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
Total amyloid-beta 1-40122.9 ± 426.51-15.9 ± 20.57-21.0 ± 19.578.72 ± 31.692.0 ± 29.2110.2 ± 98.14-14.6 ± 23.694.96 ± 90.19638.5 ± 1054.28-17.9 ± 34.08-36.96 ± 46.8238.06 ± 47.51
Total amyloid-beta 1-4225.3 ± 100.7152.0 ± 104.3541.7 ± 38.68192.8 ± 127.96414.7 ± 292.18376.1 ± 295.925.87 ± 24.52-29.4 ± 55.90633.6 ± 471.79197.5 ± 115.25915.5 ± 1361.8687.8 ± 124.68
Free amyloid-beta 1-4228.6 ± 113.70-33.9 ± 13.98-54.3 ± 39.96-57.2 ± 55.80-81.65 ± 21.67-15.2 ± 189.05-19.0 ± 17.69-2.5 ± 62.6611.6 ± 167.59-96.3 ± 2.26-95.0 ± 1.88-57.7 ± 29.76
SecondaryBiomarker: Total Amyloid-beta 1-42 in Plasma

Biomarker: Total Amyloid-beta 1-42 in plasma, mean percent change from baseline

Time frame:
Day 29 in SAD; Day 85 in MAD
Reported as:
Mean · % change
Biomarker: Total Amyloid-beta 1-42 in Plasma
% changePlacebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADPlacebo: MADMedi1814 300 mg IV: MADMedi1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
Biomarker: Total Amyloid-beta 1-42 in Plasma19.6 ± 34.5140132.5 ± 4379.9341107.0 ± 43509.8946667.9 ± 29628.0978534.5 ± 22773.9644050.9 ± 15776.4045404.0 ± 1808.13-32.0 ± 45.6530272.4 ± 14834.8084652.8 ± 44649.1643415.3 ± 13760.0797140.1 ± 34151.47
SecondaryMedi1814 Concentration in CSF Samples

Medi1814 concentration in CSF Samples; number of sampled subjects with a value above the lower limit of quantification

Time frame:
SAD Day 29; MAD Day 85
Reported as:
Number · Participants
Medi1814 Concentration in CSF Samples
ParticipantsMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADMedi1814 300 mg IV: MADMedi1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
First dose (day 1-29)0 ± 0.940 ± 2.161 ± 2.782 ± 2.234 ± 7.690 ± 3.56NA ± NANA ± NANA ± NANA ± NA
Third dose (day 57-85)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA1 ± 1.865 ± 1.616 ± 5.380 ± 3.29
SecondaryImmunogenicity: Anti-drug Antibody Titer

Immunogenicity: Anti-drug antibody titer, subject counted if titer 50 or greater on any test, else 0 if all \<50

Time frame:
4 months SAD (6 tests over 4 months; week 1, 2, 4, 8, 12, 16); 7 months MAD (7 monthly tests)
Reported as:
Number · Participants
Immunogenicity: Anti-drug Antibody Titer
ParticipantsPlacebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC : SADPlacebo: MADMedi1814 300 mg IV: MADMedi1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
Immunogenicity: Anti-drug Antibody Titer000000000000

Adverse events

Collected over From baseline until day 113 (4 months) in SAD Study Part 1; From baseline until day 169 (7 months) in MAD Study Part 2. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: SAD0/12 (0%)0/12 (0%)5/12 (41.7%)
Medi1814 25 mg IV: SAD0/3 (0%)0/3 (0%)1/3 (33.3%)
Medi1814 100 mg IV: SAD0/6 (0%)0/6 (0%)3/6 (50%)
Medi1814 300 mg IV: SAD0/6 (0%)0/6 (0%)3/6 (50%)
Medi1814 900 mg IV: SAD0/6 (0%)0/6 (0%)6/6 (100%)
Medi1814 1800 mg IV: SAD0/6 (0%)0/6 (0%)1/6 (16.7%)
Medi1814 100 mg SC: SAD0/6 (0%)0/6 (0%)4/6 (66.7%)
Placebo: MAD0/8 (0%)0/8 (0%)3/8 (37.5%)
Medi1814 300 mg IV: MAD0/6 (0%)0/6 (0%)4/6 (66.7%)
Medi1814 900 mg IV: MAD0/6 (0%)0/6 (0%)3/6 (50%)
Medi1814 1800 mg IV: MAD0/6 (0%)0/6 (0%)2/6 (33.3%)
Medi1814 200 mg SC: MAD0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPlacebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADPlacebo: MADMedi1814 300 mg IV: MADMedi1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MAD
Abdominal pain upperGastrointestinal disorders0/120/30/60/60/60/60/60/80/60/62/60/6
DizzinessNervous system disorders1/120/30/60/62/60/60/60/81/60/60/60/6
HeadacheNervous system disorders2/121/31/60/60/61/61/60/81/60/61/61/6
Sinus bradycardiaCardiac disorders0/120/30/60/60/60/60/60/80/61/60/60/6
VertigoEar and labyrinth disorders0/120/30/60/61/60/60/60/80/60/60/60/6
DiarrhoeaGastrointestinal disorders0/120/30/60/60/60/60/60/80/61/61/61/6
PyrexiaGeneral disorders0/120/30/60/60/60/60/60/80/61/60/60/6
FatigueGeneral disorders0/120/30/60/61/60/60/60/80/60/60/60/6
Injection site painGeneral disorders0/120/30/60/60/61/60/60/80/60/60/60/6
NasopharyngitisInfections and infestations0/120/30/60/60/60/60/60/81/60/60/60/6

Baseline characteristics

All randomized subjects, Safety Analysis Population

Age, Continuous
Age, Continuous(years)Placebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADPlacebo: MADMedi1814 300 mg IV: MADMedi 1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MADTotal
Mean66.3 ± 7.2274.0 ± 8.8966.8 ± 1.9469.0 ± 6.1071.8 ± 5.1564.8 ± 5.9169.3 ± 4.8470.0 ± 5.9071.7 ± 6.6270.8 ± 6.6262.5 ± 6.1669.3 ± 8.7168.5 ± 6.55
Sex: Female, Male
Sex: Female, Male(Participants)Placebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADPlacebo: MADMedi1814 300 mg IV: MADMedi 1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MADTotal
Female70654135323544
Male53012533343133
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADPlacebo: MADMedi1814 300 mg IV: MADMedi 1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MADTotal
Hispanic or Latino80541615556652
Not Hispanic or Latino43125053110025
Unknown or Not Reported0000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADPlacebo: MADMedi1814 300 mg IV: MADMedi 1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MADTotal
American Indian or Alaska Native0000000000000
Asian1201101010007
Native Hawaiian or Other Pacific Islander0000000000000
Black or African American1001000000013
White101645658566567
More than one race0000000000000
Unknown or Not Reported0000000000000
Mini Mental State Exam (MMSE)
Mini Mental State Exam (MMSE)(MMSE score)Placebo: SADMedi1814 25 mg IV: SADMedi1814 100 mg IV: SADMedi1814 300 mg IV: SADMedi1814 900 mg IV: SADMedi1814 1800 mg IV: SADMedi1814 100 mg SC: SADPlacebo: MADMedi1814 300 mg IV: MADMedi 1814 900 mg IV: MADMedi1814 1800 mg IV: MADMedi1814 200 mg SC: MADTotal
Mean21.8 ± 3.0222.0 ± 2.6522.3 ± 3.2722.5 ± 3.7322.2 ± 2.9921.0 ± 2.0023.2 ± 2.0422.1 ± 2.4819.8 ± 2.5820.2 ± 1.7220.0 ± 2.4522.5 ± 2.5921.6 ± 3.07
08

Study locations

10 sites
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Panorama City, California 91402, United States
  • Research Site
    Hallandale, Florida 33009, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Miami, Florida 33165, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Baltimore, Maryland 21225, United States
  • Research Site
    Oklahoma City, Oklahoma 73112, United States
  • Research Site
    Salt Lake City, Utah 84106, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Sep 2016, 31 months.

Results were first posted in Jun 2019, 2 years 8 months after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 31 months is above that.

Counting every sponsor, half of 234 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2014
First posted
Jan 15, 2014
StartActual
Feb 4, 2014
Primary completionActual
Sep 15, 2016
CompletionActual
Sep 15, 2016
Results first posted
Jun 3, 2019
Last update
Jun 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02036645
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 15, 2014
Start date
Feb 4, 2014
Primary completion
Sep 15, 2016
Completion
Sep 15, 2016
Results posted
Jun 3, 2019
Last update
Jun 3, 2019

Study contacts

Thor Ostenfeld, MD
study director · AstraZeneca
David Han, MD
principal investigator · Glendale Parexel Early Phase Clinical Unit

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion